Anthony G. Johnson - President and CEO @ Goldfinch Biopharma

Overview

CB Rank (Investor)

Anthony G. Johnson is the President and CEO at Goldfinch Biopharma. AttendedThe University of New South Wales.

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Companion Spine	Viscogliosi Brothers	Yes	Series A - Companion Spine	obfuscated obfuscation
obfuscated obfuscation	Companion Spine	Viscogliosi Brothers	Yes	Series A - Companion Spine	obfuscated obfuscation
obfuscated obfuscation	Cardioxyl Pharmaceuticals	OrbiMed	Yes	Series B - Cardioxyl Pharmaceuticals	obfuscated obfuscation

Number of Current Jobs

Number of Past Jobs

is the

President and CEO

. Additionally,

has had

past jobs including

SVP, Early Clinical Development

Organization Name	Title At Company	Start Date	End Date
AstraZeneca	SVP, Early Clinical Development	Apr 2014	Nov 2017
OrbiMed	Venture Partner	Oct 2012	Dec 2013
AltheRx Pharmaceuticals	Pharmaceutical Consultant	Apr 2012	Sep 2012
Bristol-Myers Squibb	VP Discovery Medicine Clinical Pharmacology	Nov 2006	Mar 2012
GlaxoSmithKline	Vice President, Discovery Medicine	Feb 2001	Oct 2006

Hub Name	CB Rank (Hub)
Cambridge Early Stage Companies	89,199
East Coast Health Care Companies with Early Stage Venture Funding	61,977
Northeastern US Early Stage Companies With Fewer Than 100 Employees	27,389
Northeastern US Biotechnology Companies with Early Stage Venture Funding	65,744
Biotechnology Early Stage Companies With Fewer Than 50 Employees	27,527
New England Early Stage Companies	51,091
Medical Device Companies With Fewer Than 50 Employees (Top 10K)	3,587
New England Startups	20,140
Private Cambridge Companies	24,804
New England Health Care Companies (Top 10K)	8,565